iShares S&P GSCI Commodity-Indexed Trust ETF vs Medpace Holdings Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.23 (market cap $1.02B), while Medpace Holdings Inc trades at $618.69 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 16.5× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 1,256,221). Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Medpace Holdings Inc for 14 Days on average.
| GSG | MEDP | |
|---|---|---|
Market Cap | $1.02B | $16.82B |
Volume | 1,256,221 | 223,093 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $630.19 |
52-Week Low | $22.45 | $393.42 |
Typical Hold Time | 40 Days | 14 Days |
Enterprise Value | — | $16.44B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →